Basel, January 27, 2014 - Novartis is pleased to announce that it has been named among the 2014 Corporate Knights Global 100.
Corporate Knights announced the results of its 2014 Global 100 Most Sustainable Corporations in the World (Global 100) index today at the World Economic Forum in Davos.
"Our inclusion in the Global 100 list is a testimony to our longstanding commitment to corporate responsibility," said Joseph Jimenez, CEO of Novartis. "Being recognized among the top 100 sustainability performers in the world underscores that doing business responsibly is a core part of Novartis."
Inclusion in the index is determined using 12 quantitative social, environmental and governance indicators, such as innovation capacity, employee turnover and leadership diversity.
Novartis aims to improve global health. Through our business, we make an important contribution to society: We discover and develop innovative medicines and vaccines. We collaborate with others to help address some of the world's greatest health challenges. To earn the trust of these collaborators and our customers, we need to do business responsibly, in a way that underscores our mission of caring and curing. We work to control and eliminate diseases, pioneer new business approaches to reach under-served patients, and find new treatments to improve health in developing countries. We also care for our associates, strive to positively contribute to our communities, and protect the environment. We conduct business ethically, maintaining a Code of Conduct and governance system to ensure associates uphold our values.
Recent recognition for our corporate responsibility activities includes being listed in the STOXX Global ESG Leaders Index for the third consecutive year; being recognized among the 25 best multinational employers by Great Place to Work® Institute; and being ranked top pharmaceutical company in Fortune's World's Most Admired Companies for the third year in a row.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 133,000 full-time equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis
Novartis Media Relations
Central media line: +41 61 324 2200
Novartis Global Media Relations
+ 41 61 324 7999 (direct)
+ 41 79 593 4202 (mobile)
Novartis Global Media Relations
+ 41 61 696 8653 (direct)
+ 41 79 536 9755 (mobile)
e-mail: [email protected]
For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis. For questions about the site or required registration, please contact: [email protected].
Novartis Investor Relations
|Central phone:||+41 61 324 7944|
|Samir Shah||+41 61 324 7944|
|Pierre-Michel Bringer||+41 61 324 1065|
|Thomas Hungerbuehler||+41 61 324 8425|
|Isabella Zinck||+41 61 324 7188|
|Stephen Rubino||+1 862 778 8301|
|Jill Pozarek||+1 212 830 2445|
|Susan Donofrio||+1 862 778 9257|
This press release contains expressed or implied forward-looking statements, including statements that can be identified by terminology such as "expects," or similar expressions. Such forward-looking statements reflect the current views of the Group regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results expressed or implied by such statements. These expectations could be affected by, among other things, risks and factors referred to in the Risk Factors section of Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update it in the future.